Overview
- The round was co-led by Oak HC/FT and General Catalyst, with OpenAI, Thrive Capital, Menlo Ventures and others participating, bringing total funding to more than $225 million.
- Annie Lamont and Hemant Taneja will join the board, following the earlier addition of former Pfizer CSO Mikael Dolsten.
- The company introduced Chai 2, a zero‑shot generative platform for de novo antibody design that it reports achieves double‑digit experimental hit rates, with results described in preprints.
- Chai says its models are built to optimize drug‑like properties to pursue historically undruggable targets and compress design‑to‑validation timelines.
- Founded in 2024 and led by CEO Josh Meier, the company plans to speed research, product development and commercialization of its AI drug design tools.